0.9% sodium chloride aqueous solution for IV infusion clinical trials

A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab), with an optional 24-week doubleblind, placebocontrolled extension phase in participants with idiopathic pulmonary fibrosis

This study is testing a new medicine called zampilimab for idiopathic pulmonary fibrosis (IPF). It aims to see if two different doses of zampilimab are safe and work better than a dummy medicine over 24 weeks, with an optional longer period.